Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

TCGA-BA-A4IH-01A-11R-A266-07

50c70edc-5cbb-533e-95c8-9e6318f9735d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
sex
male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.460
  • PANCREAS_BETA_CELLS+0.450
  • SPERMATOGENESIS+0.380
  • G2M_CHECKPOINT+0.310
  • KRAS_SIGNALING_DN+0.140
  • UV_RESPONSE_UP+0.020
  • KRAS_SIGNALING_UP+0.010
  • UV_RESPONSE_DN-0.010
  • MYC_TARGETS_V1-0.020
  • HEDGEHOG_SIGNALING-0.030

Top 10 suppressed

  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.370
  • COAGULATION-0.360
  • APICAL_JUNCTION-0.350
  • MYOGENESIS-0.340
  • MYC_TARGETS_V2-0.330
  • P53_PATHWAY-0.330
  • ANGIOGENESIS-0.320
  • PI3K_AKT_MTOR_SIGNALING-0.320
  • OXIDATIVE_PHOSPHORYLATION-0.300
  • NOTCH_SIGNALING-0.290

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BS_HHPA8NJ2
brain-umap@2
medulloblastoma0.895
2BS_7FWZ518S
brain-umap@2
medulloblastoma0.862
3MNG1226
mng-umap@100
0.860
4SRR33346963
bladder-landscape@3
0.860
5SRR23303770
bladder-landscape@3
0.859
6C3L-02616
lung-landscapes@6
cohortMD10.851
7BS_W311713R
brain-umap@2
medulloblastoma0.849
8BS_NZ71XCG3
brain-umap@2
medulloblastoma0.843
9TCGA-DQ-7591-01A-11R-2081-07
head-neck@1
0.837
10TCGA-BB-4224-01A-01R-1436-07
head-neck@1
0.832

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 7 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.460Inavolisib— uncovered
PANCREAS_BETA_CELLS0.450Cobimetinib— uncovered
SPERMATOGENESIS0.380Inavolisib— uncovered
G2M_CHECKPOINT0.310Inavolisib— uncovered
KRAS_SIGNALING_DN0.140Remibrutinib— uncovered
UV_RESPONSE_UP0.020Idelalisib— uncovered
KRAS_SIGNALING_UP0.010Inavolisib— uncovered